Trump has a 'small personal financial interest' in hydroxycholorquine drugmaker. Allies have bigger stakes.

Sanofi's hydroxychloroquine drug
(Image credit: Gerard Julien/AFP/Getty Images)

President Trump has been promoting the malaria and lupus drug hydroxychloroquine to treat COVID-19 "with all of the enthusiasm of a real estate developer," even as the medical experts on his coronavirus task force have repeatedly "warned against overselling a drug yet to be proved a safe remedy, particularly for heart patients," The New York Times reports. Some hospitals in Sweden stopped using hodroxycholoriquinine to treat the coronavirus due to adverse side effects, and the International Society of Antimicrobial Chemotherapy rejected a positive French study it had published on the drug, cited by Trump.

Dr. Anthony Fauci, the top U.S. infectious disease officials, has warned publicly and privately against promoting the drug absent studies showing its effectiveness, and "behind the scenes, career health officials have raised even stronger warnings about the risk to some Americans' heart health and other complications, but been warned not to publicly speak out and potentially contradict Trump," Politico reports. "Trump's focus on the drugs ... has increasingly warped his administration's response. Health officials have been told to prioritize the anti-malaria drugs over other projects that scientists believe have more potential to fight the outbreak." So...

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.